Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL - a proprietary, enhanced-bioavailability resveratrol formulation - is in a Phase IIa clinical trial for Parkinson's disease. The JOTROL delivery platform allows resveratrol to be consumed in an easily consumable, oral softgel in a patented micellar form. Delivered via the JOTROL platform, resveratrol infuses blood plasma and the central nervous system, and crosses the blood brain barrier, unlocking the compound's potential as a therapeutic for neurodegenerative and neurological diseases, without the GI issues. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a softgel capsule. The Company also commercializes Nugevia, a consumer longevity supplement. It also has rights in ALA-002.
Back to dashboard
Company Information
About this company
Key people
Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Alison D. Silva
President, Chief Operating Officer, Director
Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Marshall A. Hayward
Co-Founder, Chief Scientific Officer, Director
Saleem Elmasri
Chief Financial Officer
Tomas J. Philipson
Director
Nicholas H. Hemmerly
Independent Director
Julie Kampf
Independent Director
Holger Weis
Independent Director
Click to see more
Key facts
- Shares in issue770,081.00
- EPICJUNS
- ISINUS48208B3024
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$4.09m
- Employees5
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.